The positives for this big drugmaker appear to outweigh the negatives.

For a while, it seemed that nothing could go wrong for Eli Lilly ( LLY -0.20% ) . Surging sales for Lilly's type 2 diabetes drug Mounjaro and great expectations for its obesity drug Zepbound fueled massive gains for the pharma stock.

Along the way, Lilly became the largest healthcare company on the planet based on market cap . However, the story hasn't been so great for the drugmaker since last summer. Its share price remains more than 20% below the peak set in August 2025. Should investors bail on the once high-flying stock? Not according to Wall Street.

Behind Lilly's sell-off

We can't pin the blame on Lilly's steep share price decline on just one factor. There are several reasons behind the big pharma s

See Full Page